Wedoany.com Report-Nov. 26, Novo Nordisk has announced positive mid-stage clinical results for its experimental obesity and diabetes drug amycretin, leading to a rise of more than 5 percent in its Denmark-listed shares.

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark,

Amycretin is a dual-agonist therapy that targets both GLP-1 and amylin hormones, offering a different mechanism from Novo's current blockbuster Wegovy (semaglutide). The Phase 2 trial, involving 448 adults with type 2 diabetes inadequately controlled on metformin (with or without an SGLT2 inhibitor), compared once-weekly subcutaneous and daily oral formulations against placebo over 36 weeks.

The injectable version achieved average weight loss of up to 14.5 percent, while the oral tablet delivered up to 10.1 percent. No weight-loss plateau was observed during the study period, indicating potential for further reduction with longer treatment duration. Amycretin also met its primary endpoint by significantly lowering HbA1c, with up to 89.1 percent of patients reaching levels below 7 percent. Side effects were mainly mild to moderate gastrointestinal symptoms.

The results strengthen Novo Nordisk's pipeline as it seeks to maintain leadership in the fast-growing weight-management and diabetes treatment market. Amycretin is viewed by analysts as one of the company's most promising next-generation candidates.

BMO Capital analyst Evan Seigerman noted that the absence of a weight-loss plateau and the strong efficacy data represent a positive development for Novo Nordisk's competitive positioning.

Kepler Cheuvreux analyst David Evans stated: "The level of weight-loss seen bodes well not only for its potential in diabetes but also in obesity."

Morningstar analyst Karen Andersen forecasts peak annual sales for amycretin of approximately $8 billion by 2034 across both diabetes and obesity indications, assuming a launch in 2029.

Novo Nordisk plans to advance amycretin into Phase 3 trials in 2026 for both subcutaneous and oral administration. The latest data follow recent updates on other pipeline programmes and underscore the company’s ongoing investment in innovative metabolic therapies.